ArriVent Posts Wider Loss in Fiscal Q2

ArriVent BioPharma (NASDAQ:AVBP), a clinical-stage oncology company, reported its second quarter 2025 earnings on August 11, 2025. The most important update was a wider net loss than expected--the company posted a GAAP loss per share of $(0.90), compared to analyst expectations of $(0.71)--as research and development spending jumped in the six months ended June 30, 2025, driven by the ongoing expansion of its pipeline and a sizable one-time payment for a new partnership. Cash and short-term investments grew, aided by an $81.1 million fundraise in July 2025, extending the cash runway through mid-2027. The period was highlighted by clinical milestones for the company’s lead drug candidate and the expansion of its development pipeline, but also by rapidly accelerating expenses. Source: Analyst estimates for the quarter provided by FactSet. ArriVent BioPharma is a biotechnology company focused on developing targeted therapies for cancer. Its lead candidate is firmonertinib, an oral small molecule drug known as an epidermal growth factor receptor (EGFR) inhibitor. The company targets non-small cell lung cancer (NSCLC) patients with specific genetic mutations where treatment options are limited.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool